Key facts
- This page summarizes Patrick John Casey's Form 4 filing for Legend Biotech Corp (LEGN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2026, 16:05.
Patrick John Casey - 30 Jun 2026 Form 4 Insider Report for Legend Biotech Corp (LEGN)
- Reporting relationship
- Director
- Issuer ticker
- LEGN
- Reported as of
- 30 Jun 2026
- Net transaction value
- -$88,800
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2026, 16:05:24 UTC
- Prior SEC filing
- 18 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Pepin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Patrick John Casey filed Form 4 for Legend Biotech Corp (LEGN) on 02 Jul 2026.
Change
- Previous filing in this sequence was filed on 18 Mar 2026.
- Current net transaction value: -$88,800.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002068365
Primary reporting owner
Casey Patrick John
- Relationship
- Director
- Address
- C/O LEGEND BIOTECH CORP, 2101 COTTONTAIL LANE, SOMERSET
- Signature
- /s/ James Pepin, Attorney-in-Fact
- Signature date
- 02 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LEGN
transaction
Ordinary Shares
Sale
- Transaction value
- $88,800
- Shares
- -6,000
- Change %
- -11%
- Price
- $14.80
- Shares after
- 48,604
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
Footnote F2
The price reported in Column 4 represents the converted sales price of ADSs of $29.60 per ADS (which is equivalent to $14.80 per ordinary share).